doi: 10.1016/j.jtct.2025.08.007.
Online ahead of print.
Safe and effective addition of ruxolitinib to graft-versus-host prophylaxis in older adults undergoing reduced-intensity allogeneic hematopoietic cell transplantation
Affiliations
- PMID: 40803426
- DOI: 10.1016/j.jtct.2025.08.007
Item in Clipboard
Safe and effective addition of ruxolitinib to graft-versus-host prophylaxis in older adults undergoing reduced-intensity allogeneic hematopoietic cell transplantation
Transplant Cell Ther.
.
No abstract available
Conflict of interest statement
Declaration of competing interest Statement: Y.B.C. has consulted for Incyte, CSL Behring, MaaT Biotherapeutics, Ironwood, LifeMine, ProTGen, Generation Bio, Novo Nordisk, Editas, Alexion, and Daiichi, as well as equity for ImmunoFree and Phesi. TRS. has consulted for Bluebird Bio, Syneos Health, Qihan Biotech, Ossium Health, and Alexion Pharmaceuticals, as well as honoraria from Sanofi. ZD receives research support from Incyte, Corp., Regimmune, Corp., Taiho Oncology, Inc., and Kura Oncology, Inc., and has received consulting fees from Sanofi, Incyte, Corp., Inhibrx, RegImmune, Corp, MaaT Pharma, Forte Biosciences Inc, Medexus Pharmaceuticals, Inc, and Mesoblast Ltd.
Similar articles
-
Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.Ann Hematol. 2025 Apr;104(4):2125-2141. doi: 10.1007/s00277-025-06270-9. Epub 2025 Mar 22. Ann Hematol. 2025. PMID: 40119918 Free PMC article. Review.
-
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2023 Jun 21;6:CD009159. doi: 10.1002/14651858.CD009159.pub3. PMID: 22972135 Updated.
-
Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience.Front Immunol. 2025 Jul 14;16:1621708. doi: 10.3389/fimmu.2025.1621708. eCollection 2025. Front Immunol. 2025. PMID: 40726989 Free PMC article.
-
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.Cochrane Database Syst Rev. 2023 Jun 21;6(6):CD009159. doi: 10.1002/14651858.CD009159.pub3. Cochrane Database Syst Rev. 2023. PMID: 37341189 Free PMC article.
-
Long-term follow-up results of ruxolitinib as salvage therapy for chronic graft-versus-host disease.Hematol Transfus Cell Ther. 2025 Jul-Sep;47(3):103835. doi: 10.1016/j.htct.2025.103835. Epub 2025 May 11. Hematol Transfus Cell Ther. 2025. PMID: 40354779 Free PMC article.
LinkOut - more resources
Full Text Sources
